As Gilead plans a C-suite succession, the rash of top-level departures continues

Now that the top Gilead Sciences (GILD) executives are leaving, will a full-blown exodus occur at the biotech?

The thought arises after the company announced on Wednesday that Dr. Andrew Cheng, a 19-year Gilead veteran who was named chief medical office just five months ago, is suddenly departing. His resignation follows by just three weeks the unexpected news that chief executive John Milligan will leave at the end of the year, after just two years in that role, and that chairman John Martin will follow suit.

But even before Milligan and Martin surprised investors last month by declaring their departures, chief scientific officer Norbert Bischofberger had left last April, just two months after Kevin Young, who had been chief operating officer, also departed. So in the course of just half a year, the top of the Gilead pyramid has either left or made plans to do so.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$20

for 3 months, then $399/year

$20 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In